The persistent challenge of lupus nephritis

Clinical Reviews in Allergy and Immunology

Volumn 40, Issue 3, 2011, Pages 135-137

  Valesini, Guido ^a   Conti, Fabrizio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Glomerulonephritis; Immunosuppressive agents; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

B LYMPHOCYTE; DRUG PULSE THERAPY; HUMAN; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNITY; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOTHERAPY; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; MYELOABLATIVE AGONISTS; REMISSION INDUCTION; TOLL-LIKE RECEPTORS;

EID: 79957928981     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8210-6     Document Type: Review

References (56)

1. Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299-308 (Pubitemid 37229465)
2. Cameron JS (1999) Lupus nephritis. J Am Soc Nephrol 10:413-424
3. Austin HA 3rd, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619 (Pubitemid 16132725)
4. Boumpas DT, Austin HA 3rd, Vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745
5. Houssiau FA, Vasconcelos C, D'Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121-2131
6. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS (2009) Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatol (Oxf) 48:944-952
7. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767-76
8. Kaisho T, Akira S (2006) Toll-like receptor function and signaling. J Allergy Clin Immunol 117:979-987
9. Pasare C, Medzhitov R (2004) Toll-like receptors and acquired immunity. Semin Immunol 16:23-26 (Pubitemid 38147430)
10. Delgado MA, Deretic V (2009) Toll like receptors in control of immunological autophagy. Cell Death Differ 16:976-983
11. Ward MM (2009) Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 36:63-67
12. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP (1994) The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 21:2046-2051 (Pubitemid 24352349)
13. Faurschou M, Starklint H, Halberg P, Jacobsen S (2006) Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 33:1563-1569 (Pubitemid 44168828)
14. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria (2006) The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 54:421-32
15. Gordon C, Jayne D, Pusey C et al (2009) European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18:257-63
16. Youinou P, Pers J-O, Gershwin ME, Shoenfeld Y (2010) Geoepidemiology and autoimmunity. J Autoimmun 34:163-167
17. Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:168-177
18. Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:178-206
19. Brooks WH, Le Dantec C, Pers J-O, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:207-219
20. Round JL, O'Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiotia. J Autoimmun 34:220-225
21. Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:226-233
22. Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:234-246
23. Maverakis E, Miyamura Y, Bowen MP et al (2010) Light, including ultraviolet. J Autoimmun 34:247-257
24. Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:258-265
25. Chang C, Gershwin ME (2010) Drugs and autoimmunity - a contemporary review and mechanistic approach. J Autoimmun 34:266-275
26. Chen M, Daha MR, Kallenberg CGM (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:276-286
27. Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:287-299
28. Invernizzi P (2010) Geoepidemiology of autoimmune liver diseases. J Autoimmun 34:300-306
29. Hemminki K, Li X, Sundquist J, Sundquist K (2010) The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 34:307-313
30. Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:314-321
31. Tomer Y (2010) Hepatitis C and interferon induced thyroiditis. J Autoimmun 34:322-326
32. Zeki AA, SchivoM, Chan P et al (2010) Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 34:327-338
33. Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9:247-250
34. Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:251-258
35. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity - autoantibodies versus autoimmune disease. Autoimmun Rev 9:259-266
36. Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:267-270
37. Stojanovich L (2010) Stress and autoimmunity. Autoimmun Rev 9:271-276
38. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:277-287
39. Tobon GJ, Youinou P, Saraux A (2010) The environment, geoepidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:288-292
40. Chen M, Kallenberg CGM (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:293-298
41. Biggioggero M, Meroni PL (2010) The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 9:299-304
42. Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 9:305-310
43. Ranque B, Mouthon L (2010) Geoepidemiology of systemic sclerosis. Autoimmun Rev 9:311-318
44. Berkun Y, Padeh S (2010) Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 9:319-324
45. Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:325-329
46. Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9:330-334
47. Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:335-341
48. Deane S, Teuber SS, Gershwin ME (2010) The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 9:342-349
49. Lambert J-F, Nydegger UE (2010) Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 9:350-354
50. Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:355-365
51. Segelmark M, Hellmark T (2010) Autoimmune kidney diseases. Autoimmun Rev 9:366-371
52. Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:372-378
53. Meyer N, Levy Y (2010) Geoepidemiology of myasthenia gravis. Autoimmun Rev 9:383-386
54. Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9:387-394
55. Bhat A, Naguwa S, Cheema G, Gershwin ME (2010) The epidemiology of transverse myelitis. Autoimmun Rev 9:395-399
56. Leung PSC, Shu S-A, Kenny TP, Wu P-Y, Tao M-H (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:400-405